- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02668133
Zinc Absorption From SQ-LNS With and Without Phytase
Efficacy of Exogenous Phytase Added to Small Quantity Lipid Nutrient Supplements (SQ-LNS) on the Fractional and Total Absorption of Zinc Among Young Children in the Gambia: A Double-blind Randomized Controlled Trial With a Cross-over Design
Background: Community based-intervention trials conducted among infants and young children in low- and middle-income countries have found that zinc supplementation of young children (in the form of liquid supplements or dispersible tablets) increases linear growth and weight gain, and reduces the prevalence of diarrhea and respiratory infections, and lowers all-cause mortality. Aside from supplements, additional dietary zinc can also be provided through "home-fortification" of complementary foods with small-quantity lipid-based nutrient supplements (SQ-LNS; 20g/d), which are typically formulated as a peanut-based paste enriched with a vitamin and mineral complex containing 8 mg elemental zinc (as ZnSO4). However, the efficacy of LNS as a delivery vehicle for preventive zinc supplementation remains uncertain. Two recent studies, which provided LNS containing 4-10 mg Zn daily for 6-9 months found no significant differences in plasma zinc concentrations at the end of the intervention period compared to placebo.
This lack of response may be due to the reduced absorption of zinc when it is part of a complex food matrix and provided with cereal-based meals; both SQ-LNS and cereal grains contain moderate to high concentrations of phytate, the main dietary factor known to substantially reduce zinc absorption. The addition of exogenous phytases is an efficacious strategy to reduce the phytate content of foods, and increase the bioavailability of dietary zinc; however, the efficacy of this approach has not yet been demonstrated for SQ-LNS.
Objective: The overall objective of the study is to assess the efficacy of adding exogenous phytase to SQ-LNS by investigating intra-individual differences in the fractional absorption of zinc (FAZ) among children who receive additional dietary zinc (8 mg/d) from SQ-LNS with or without phytase.
Trial approach: The study will be a double-blind randomized controlled clinical trial, designed to permit within-child comparisons of zinc absorption from SQ-LNS, with or without exogenous phytase, by using the triple stable-isotope ratio tracer technique. The clinical study will enroll 34 children between the ages of 18-23 months. The main outcome of interest is the intra-individual difference in the FAZ from porridge-based meals containing SQ-LNS with and without phytase. Up to an' additional 36 children will be enrolled in a pilot feeding study to determine portion sizes of study meals.
Trial setting: Keneba, The Gambia
Trial interventions:
The SQ-LNS (20g) used in this study will be provided by Nutriset, S.A.S. The exogenous phytase (DSM phytase Tolerase 20000G) is derived from Aspergillus niger; phytase will be added to the SQ-LNS during the production phase, and will be enzymatically active in vivo at the time of consumption.
Feeding Protocol and Study Diet: The study diet for the 2day absorption study will consist of the following: 1) Two stable-isotope labeled test meals per day (porridge made from locally procured non-fermented cereal, mixed with 10 g of SQ-LNS), with children randomized to receive either SQ-LNS with phytase or SQ-LNS without phytase on the first day and the alternative product on the second; 2) One additional standardized meal per day (e.g. rice with sauce); 3) Low-zinc, low-phytate food (e.g. bananas) consumed ad libitum if requested (with the exception of 1 hour before and 2 hours after each test meal). Children will be fed by their caregivers under supervision by a study fieldworker. The SQ-LNS product (without phytase) will be provided to children twice per day for one day prior to the start of the stable isotope absorption studies, in order to habituate children to the study diet and location. Children will attend the study clinic daily for four days and will be enrolled in the study for a total of ten days.
Zinc absorption studies: The FAZ of zinc will be measured by a triple-isotope tracer ratio technique, using orally administered extrinsic labels (Zn-67 and Zn-70) and intravenous Zn-68. Urine samples, collected pre- and post-isotope administration (d 1, 5-9) will be analyzed for zinc isotope ratios by ICP-MS. FAZ will be calculated based on the mean isotopic ratios obtained from the enriched urine samples, and based on the tracer:tracee ratio method. TAZ will be calculated by multiplying FAZ by total zinc intake from the test meals.
Data Collection: The following information will be collected from each subject: brief medical history; physical examination; weight and height; daily morbidity and pre-intervention blood sampling for hemoglobin, complete blood count and plasma zinc concentration, malaria and systemic inflammation (C-reactive protein and α-1-acid glycoprotein).
Study Overview
Status
Conditions
Intervention / Treatment
- Dietary supplement: the nutritional supplement to be used in this trial is a SQ-LNS
- Dietary supplement: 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc
- Dietary supplement: 1 mg isotopically enriched 68Zn
- Dietary supplement: lipid-based nutrient supplement (SQ-LNS) with phytase
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Kiang, Gambia
- Keneba Clinic
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Signed informed consent from at least one parent, including consent for samples to be shipped outside of The Gambia
- Age 18-23 months
- non-breast feeding children and consumption of coos porridge
- Previous consumption of peanut based products with no known adverse reaction
Exclusion Criteria:
- Weight-for-height z-score (WHZ) <-3 Z with respect to WHO 2006 standards*
- Presence of bipedal oedema
- Severe illness warranting hospital referral
- Congenital abnormalities potentially interfering with micronutrient metabolism
- Chronic medical condition (e.g. malignancy) requiring frequent medical attention
- Known HIV infection of index child or child's mother
- Currently consuming vitamin or mineral supplements or zinc- or iron-fortified infant formulas/foods
- Diarrhoea (>3 liquid or semi-liquid stools per day) within the past 7 days
- Symptomatic acute or chronic febrile infection within the past 7 days
- Hemoglobin < 70 g/L*
- Positive rapid diagnostic test for malaria antigenemia (HRP2)* * Exclusion criteria for main metabolic study only (not criteria for the pilot feeding study, as anthropometric and biochemical data will not be collected
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: lipid-based nutrient supplement SQ-LNS
• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day) 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution 1 mg isotopically enriched 68Zn intravenously |
Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day
delivered orally in sugar solution
administered intravenously
|
Experimental: lipid-based nutrient supplement SQ-LNS with phytase
• Small quantity lipid nutrient supplement SQ-LNS containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration ~500 FTU/20 g SQ-LNS added during manufacturing 0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc delivered orally in sugar solution 1 mg isotopically enriched 68Zn intravenously |
delivered orally in sugar solution
administered intravenously
• Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day).
Exogenous phytase (projected concentration ~500 FTU/20 g SQ-LNS) added during manufacturing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Fractional absorption of zinc
Time Frame: 10 days
|
Fractional absorption of zinc is estimated using the triple zinc stable isotope tracer ratio technique.
67Zn and 70Zn are administered orally and 68Zn is administered intravenously.
The urinary enrichment of the three isotopes is measured over 5 days (ICP-MS) and tracer:tracee ratios are calculated.
|
10 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Total absorption of zinc
Time Frame: 10 days
|
Total absorption of zinc is estimated by multiplying fractional absorption of zinc by dietary zinc intake.
|
10 days
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Andrew Prentice, PhD, Medical Research Council The Gambia
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- SCC 1420
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Individuals at Risk of Zinc Deficiency
-
Yonsei UniversityNot yet recruitingHealthy Elderly Individuals With High LDL-cholesterol or Risk of Cardiovascular DiseaseKorea, Republic of
-
Heidelberg UniversityUnknownFocus: Immunocompromised Individuals at High Risk of Aqcuiring Invasive AspergillosisGermany
-
InLight SolutionsTruTouch TechnologiesCompletedHealthy Individuals | At Least 21 Years of AgeUnited States
-
University of PittsburghRecruitingNormal and Overweight Individuals at High-risk of DiabetesUnited States
-
Northwestern UniversityWithdrawnIndividuals at Risk for DepressionUnited States
-
University of AdelaideCompletedIndividuals at Risk of Developing DiabetesAustralia
-
Zekai Tahir Burak Women's Health Research and Education...Ankara City Hospital BilkentCompletedPreterm Infant | Effect of Drugs | Zinc Deficiency DiseaseTurkey
-
Frederiksberg University HospitalCompleted
-
Oregon Research InstituteCompleted
-
Raúl Sampieri CabreraCompletedStudents at Risk of Obtaining Low Academic PerformanceMexico
Clinical Trials on the nutritional supplement to be used in this trial is a SQ-LNS
-
CAMC Health SystemTerminated
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of Sheffield; National Institute for Health Research: CLAHRC YH; The... and other collaboratorsCompletedChronic Obstructive Pulmonary Disease (COPD)United Kingdom
-
VA Office of Research and DevelopmentVA Boston Healthcare SystemRecruitingMild Cognitive Impairment | Mild Traumatic Brain Injury | Moderate Traumatic Brain InjuryUnited States
-
Kanuni Sultan Suleyman Training and Research HospitalCompleted
-
Lawson Health Research InstituteWithdrawnFemale, Late Life DepressionCanada
-
TVA Medical Inc.Completed
-
Tampa General HospitalWithdrawnEffect of Protocolized Sedation on Days of Mechanical Ventilation in the ICUUnited States
-
Memorial Sloan Kettering Cancer CenterNational Institutes of Health (NIH)CompletedOvarian Cancer | Fallopian Tube Cancer | Vulvar Cancer | Vaginal Cancer | Peritoneal Cancer | Uterine CancerUnited States
-
Moorfields Eye Hospital NHS Foundation TrustCompleted
-
Campus Bio-Medico UniversityPolitecnico di MilanoRecruitingPancreatic NeoplasmsItaly